Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Zavicefta (ceftazidime/avibactam by Year
Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide reported YoY (%) (%)
Pfizer Zavicefta (ceftazidime/avibactam: 9.0% in FY2025, down 6.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Zavicefta (Outside the U.S. and Canada) | 638 | 586 | 9% | 9% | — | — | — | 638 | 586 | 9% | 9%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.0% | -6.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 15.0% | +1.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 14.0% | +32.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | -18.0% | -81.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 63.0% | +35.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2020 | Dec 31, 2020 | 28.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Pfizer Zavicefta (ceftazidime/avibactam (%), annual FY2020–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zavicefta-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?